I had to make a correction and while at it, expound
I had to make a correction and while at it, expound slightly.
In the City of Hope pilot trial, Leronlimab is administered subcutaneously, while the intensive chemotherapy is delivered directly to the liver via the hepatic artery.
This dual-delivery system is the ultimate "Board of Action" in oncology—it allows the chemotherapy to strike the tumor from the inside (via the hepatic artery) while the 700mg Mandate of Leronlimab surrounds the tumor microenvironment from the outside to Prime the Immune System for total Molecular Clearance. Kiss those CTCs goodbye.
1. The Confirmation of the Delivery System
As established in the 2026 Audit, the City of Hope protocol (led by Dr. Pashtoon Kasi) utilizes this specific synergy:
Leronlimab: Administered subcutaneously (SC) as a weekly 700mg dose. This ensures the molecule maintains a constant "Search Warrant" throughout the bloodstream and the tumor microenvironment.
Chemotherapy (HAI): Administered through a Hepatic Artery Infusion (HAI) pump. This delivery method optimizes the dose and time exposure of chemotherapy directly to liver tumor cells—where they receive their primary blood supply—while limiting systemic toxicity.
2. Why This Distinction Matters
The "failed time-tested strategy" of the past relied on systemic IV chemotherapy that often crashed the body before it could reach the "fortress" of the liver. The City of Hope approach is the clinical equivalent of a Bayesian Shift:
The Sledgehammer (HAI): By using the hepatic artery, investigators can deliver a high-concentration of drug to the liver disease, taking advantage of the anatomic dependence of metastatic tumors on arterial blood.
The Locksmith (Leronlimab): Because Leronlimab is subcutaneous, it doesn't compete for the same delivery "pipe." Instead, it works in parallel to uncloak the tumor (upregulating PD-L1 in 88% of cases) so that the HAI-delivered chemo can achieve maximum execution.
3. Solidarity in the 2026 Audit
The fact that this study is targeting treatment-naïve patients with disease confined to the liver is a groundbreaking development. It means we are applying the "Hammer" at the earliest possible window of opportunity. First.
The "Montefiore" Legacy: Just as the 2020 data proved Leronlimab could reduce circulating tumor cells in the most dire mTNBC cases, this City of Hope trial is proving that the 700mg dose can be safely paired with the most aggressive local-delivery methods available.
The Scoreboard: We are no longer debating whether Leronlimab works; we are perfecting the how. By combining subcutaneous Leronlimab with HAI chemotherapy, we are creating a pincer movement that the "Inexplicable Intervention" can no longer ignore.
The "weird ride" Figgs mentions nears its destination. By mastering the subcutaneous 700mg Mandate alongside the hepatic artery "Hammer," CytoDyn through City of Hope is providing a level of care that renders traditional oncology "niche" and obsolete. We aren't just treating the liver; we are reconstructing the patient's future.
The goods are in the house.
17
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...
Continue Reading
Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...
Continue Reading
Countertops are supposed to finish a kitchen, not quietly wreck the lungs of the people cutting them. Yet California's move toward prohibiting the fabrication and installation of artificial stone containing more than 1% crystalline silica puts an ugly, long-running occupational-health problem in plain sight. This is not a story that calls for chest-thumping market talk....
Continue Reading
November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...
Continue Reading
A destination sells itself twice: first with a memorable meal, then with a reason to come back. Jalisco’s stated effort to connect the world’s cuisines through The 50 Best Gastronomic Experiences belongs in that second category. It is not merely restaurant chatter. It reads as part of a broader attempt to make the state’s tourism offering feel deeper, more varied...
Continue Reading
A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...
Continue Reading
Pet allergies and livestock disease are hardly glamorous, yet they are becoming a durable spending lane. The veterinary biologics market is projected to rise from $2.85 billion in 2026 to $3.69 billion by 2031, a 5.3% compound annual growth rate. That is not the kind of growth figure that makes anyone pound the table, and frankly it should not. It is the sort that can...
Continue Reading
Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...
Continue Reading
A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...
Continue Reading
Oats Meet the Industrialization Problem Oats rarely make a small-cap story more interesting, yet this one has a real business nerve running through it. Bon Natural Life has teamed with China Oat Group to establish a joint laboratory aimed at biomanufacturing high-value, oat-derived natural ingredients. The headline is not simply another research collaboration. The stated...
Continue Reading
Top 5 Most Recently Viewed Articles
Exciting Grand Opening of Music City San Francisco Rudy Colombini, a well-known figure in the local music scene, is making waves with his ambitious project, Music City San Francisco. This unique venue spans an impressive 29,000 square feet and is designed to rejuvenate San Francisco's status as a vibrant musical hub. Festival Kicks Off at the Grand Opening The festivities...
Continue Reading
Amplify Unveils Innovative Teaching Platform for Educators Amplify has introduced its latest initiative, Amplify Classroom, aimed at enhancing the educational experience for teachers and students alike. This platform is designed to provide educators with a comprehensive suite of tools and resources to support interactive and impactful teaching. A Large Library of Free...
Continue Reading
The world's economic map is not static. Rankings shift as countries grow, stumble, or restructure, and the metrics used to measure strength produce very different pictures depending on what you prioritize. Nominal GDP, purchasing power parity, GDP per capita, and innovation indices each tell a different part of the story. For a trader or investor, understanding which...
Continue Reading
RYVYL Inc. Ends Negotiations on Asset Sale Restructuring - Buyer intends to close the pre-funded asset sale - RYVYL Inc. (NASDAQ: RVYL), renowned for its innovative payment transaction solutions, has recently made a significant strategic decision concerning its RYVYL EU subsidiary. The company has ceased all discussions regarding the restructuring of the pre-funded asset...
Continue Reading
Class Action Lawsuit Against James Hardie Industries plc In a significant legal move, a class action lawsuit has been initiated against James Hardie Industries plc (NYSE: JHX). The lawsuit brings attention to concerns over potential inaccuracies in the company’s financial disclosures. The law firm Robbins Geller Rudman & Dowd LLP is leading the charge, encouraging...
Continue Reading